
Opinion|Videos|May 14, 2024
Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Can Close the Opioid Addiction Care Gap
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
4
The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact
5
















































































































































































































